13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
73 檔
32.2%
According to the latest 13F quarterly dataset, Silverarc Capital Management, LLC managed an equity portfolio of $962.2M at the end of Q1 2026, spanning 73 distinct U.S. exchange-listed positions.
Silverarc Capital Management, LLC executed strategic sector rebalancing during Q1 2026, establishing 25 new positions while fully exiting 20 holdings and trimming 28 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Spdr Series Trust | Stock-Other | 10.75% | -10.75% | EXIT | |
| 2 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 5.91% | -5.91% | EXIT | |
| 3 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 5.61% | -1.66% | -12.72% | |
| 4 | COGT | Cogent Biosciences Inc | Stock-Other | 5.16% | -0.01% | +5.54% | |
| 5 | CELC | Celcuity Inc | Stock-Other | 4.17% | +1.28% | -4.59% | |
| 6 | IMNM | Immunome Inc | Stock-Other | 4.13% | +0.31% | +64.29% | |
| 7 | KOD | Kodiak Sciences Inc | Stock-Other | 3.86% | -1.65% | -3.05% | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 3.71% | -3.71% | EXIT | |
| 9 | ABVX | Abivax Sa-adr | Stock-Other | 3.44% | -1.09% | -28.34% | |
| 10 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 3.36% | -0.57% | +94.55% | |
| 11 | ERAS | Erasca Inc | Stock-Other | 3.06% | -0.66% | +40.55% | |
| 12 | ASND | Ascendis Pharma A/S | Stock-Other | 2.91% | -2.91% | EXIT | |
| 13 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.76% | +2.22% | -13.56% | |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.72% | +0.87% | +125.08% | |
| 15 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.35% | -0.06% | -13.23% | |
| 16 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.27% | -0.93% | — | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.12% | +0.64% | +38.28% | |
| 18 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.89% | -1.89% | EXIT | |
| 19 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.70% | -1.70% | EXIT | |
| 20 | ALKS | Alkermes plc | Stock-Healthcare | 1.66% | -1.04% | — | |
| 21 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.42% | -0.59% | -1.49% | |
| 22 | IRON | Disc Medicine Inc | Stock-Other | 1.28% | -0.65% | — | |
| 23 | ✓ | Helix Acquisition CORP Iii | Stock-Other | 1.25% | +0.05% | — | |
| 24 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.17% | — | — | |
| 25 | CGON | Cg Oncology Inc | Stock-Other | 1.15% | -1.15% | EXIT | |
| 26 | IMVT | Immunovant Inc | Stock-Other | 1.05% | +1.43% | — | |
| 27 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.96% | -0.41% | -0.60% | |
| 28 | BIIB | Biogen Inc | Stock-Healthcare | 0.95% | +0.13% | -32.42% | |
| 29 | GH | Guardant Health Inc | Stock-Healthcare | 0.93% | +0.63% | +7.18% | |
| 30 | PCVX | Vaxcyte Inc | Stock-Other | 0.86% | +0.02% | -2.56% | |
| 31 | ✓ | Uniqure NV | Stock-Other | 0.83% | -0.83% | EXIT | |
| 32 | SVRA | Savara Inc | Stock-Other | 0.80% | +0.07% | — | |
| 33 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.78% | +0.17% | -1.91% | |
| 34 | ✓ | Syndax Pharmaceuticals Inc | Stock-Other | 0.76% | +0.82% | — | |
| 35 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.76% | +2.73% | — | |
| 36 | ✓ | Compugen LTD | Stock-Other | 0.72% | -0.01% | -4.71% | |
| 37 | ✓ | Celcuity Inc | Stock-Other | 0.63% | -0.63% | EXIT | |
| 38 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.62% | +0.69% | -5.56% | |
| 39 | INSM | Insmed Inc | Stock-Healthcare | 0.60% | -0.22% | -49.69% | |
| 40 | VCYT | Veracyte Inc | Stock-Other | 0.59% | +1.35% | -49.74% | |
| 41 | CERS | Cerus CORP | Stock-Other | 0.59% | +0.46% | +12.87% | |
| 42 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.58% | -0.58% | EXIT | |
| 43 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.51% | +0.96% | -4.13% | |
| 44 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.48% | -0.48% | EXIT | |
| 45 | CLYM | Climb Bio Inc | Stock-Other | 0.48% | -0.48% | EXIT | |
| 46 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.46% | -0.46% | EXIT | |
| 47 | SRZN | Surrozen Inc | Stock-Other | 0.43% | -0.43% | EXIT | |
| 48 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.40% | +0.10% | -1.89% | |
| 49 | ✓ | Zura Bio LTD | Stock-Other | 0.34% | -0.34% | EXIT | |
| 50 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.33% | -0.33% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | +2.4% | +40.55% | Add |
| 2 | ASND | Ascendis Pharma A/S | +1.5% | +153.23% | Add |
| 3 | DNTH | Dianthus Therapeutics Inc | +1.3% | -12.72% | Trim |
| 4 | GLUE | Monte Rosa Therapeutics Inc | +1.1% | +94.55% | Add |
| 5 | IMNM | Immunome Inc | +0.8% | +64.29% | Add |
| 6 | RYTM | Rhythm Pharmaceuticals Inc | +0.7% | +125.08% | Add |
| 7 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.5% | +18.51% | Add |
| 8 | 260 | Centessa Pharmaceuticals-adr | +0.3% | +1.78% | Add |
| 9 | SNDX | Syndax Pharmaceuticals Inc | +0.2% | +38.28% | Add |
| 10 | ORIC | Oric Pharmaceuticals Inc | +0.2% | -1.49% | Trim |
| 11 | SYRE | Spyre Therapeutics Inc | +0.1% | -0.60% | Trim |
| 12 | ELUT | Elutia Inc | 0% | -9.21% | Trim |
| 13 | IBIO | Ibio Inc | 0% | +113.21% | Add |
| 14 | EWTX | Edgewise Therapeutics Inc | — | +1.34% | Add |
| 15 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 16 | ✓ | Compugen LTD | 0% | -4.71% | Trim |
| 17 | CCCC | C4 Therapeutics Inc | 0% | -4.13% | Trim |
| 18 | ADGM | Adagio Medical Holdings Inc | 0% | -51.11% | Trim |
| 19 | SRZN | Surrozen Inc | -0.1% | -8.31% | Trim |
| 20 | RADX | Radiopharm Theranostics LTD | -0.1% | — | Unchanged |
| 21 | SION | Sionna Therapeutics Inc | -0.1% | -4.93% | Trim |
| 22 | PCVX | Vaxcyte Inc | -0.1% | -2.56% | Trim |
| 23 | CTNM | Contineum Therapeutics Inc-a | -0.1% | -1.89% | Trim |
| 24 | KOD | Kodiak Sciences Inc | -0.1% | -3.05% | Trim |
| 25 | CLDX | Celldex Therapeutics Inc | -0.1% | -6.64% | Trim |
| 26 | NXTC | Nextcure Inc | -0.2% | — | Unchanged |
| 27 | ABEO | Abeona Therapeutics Inc | -0.2% | +3.38% | Add |
| 28 | CERS | Cerus CORP | -0.2% | +12.87% | Add |
| 29 | TELA | Tela Bio Inc | -0.3% | -14.66% | Trim |
| 30 | FULC | Fulcrum Therapeutics Inc | -0.3% | +6.41% | Add |
| 31 | ✓ | Fulcrum Therapeutics Inc | -0.3% | — | Unchanged |
| 32 | CMPX | Compass Therapeutics Inc | -0.3% | -18.29% | Trim |
| 33 | TRVI | Trevi Therapeutics Inc | -0.3% | -5.56% | Trim |
| 34 | GH | Guardant Health Inc | -0.4% | +7.18% | Add |
| 35 | AARD | Aardvark Therapeutics Inc | -0.5% | -88.92% | Trim |
| 36 | BNTC | Benitec Biopharma Inc | -0.6% | -1.91% | Trim |
| 37 | NUVL | Nuvalent Inc-a | -0.6% | +13.96% | Add |
| 38 | BIIB | Biogen Inc | -0.9% | -32.42% | Trim |
| 39 | CGON | Cg Oncology Inc | -0.9% | -53.94% | Trim |
| 40 | COGT | Cogent Biosciences Inc | -1% | +5.54% | Add |
| 41 | CELC | Celcuity Inc | -1% | -4.59% | Trim |
| 42 | PRAX | Praxis Precision Medicines I | -1% | -13.23% | Trim |
| 43 | INSM | Insmed Inc | -1.1% | -49.69% | Trim |
| 44 | VCYT | Veracyte Inc | -1.5% | -49.74% | Trim |
| 45 | ✓ | Uniqure NV | -1.6% | -30.63% | Trim |
| 46 | URGN | UroGen Pharma Ltd. | -2.9% | -13.56% | Trim |
| 47 | GUTS | Fractyl Health Inc | -2.9% | -82.71% | Trim |
| 48 | ABVX | Abivax Sa-adr | -4.5% | -28.34% | Trim |
| 49 | ✓ | Spdr Series Trust | — | NEW | New buy |
| 50 | ZBIO | Zenas Biopharma Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 73 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPDR SERIES TRUST, 4XC1, DNTH) accounted for 32.2% of total reported equity market value during Q1 2026.
Top New Position Initiated
SPDR SERIES TRUST
市值: $105.4M
Top Position Liquidated / Trimmed
VRDN
前期市值: $10.8M
During Q1 2026, Silverarc Capital Management, LLC's top holdings by market value included SPDR SERIES TRUST (10.8%)、4XC1 (5.9%)、DNTH (5.6%). The largest single position, SPDR SERIES TRUST, represented 10.8% of total portfolio value.
In Q1 2026, Silverarc Capital Management, LLC made 89 total portfolio adjustments, initiating 25 new buys, adding to 16 positions, trimming 28 holdings, and fully liquidating 20 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.